All | KRASwild-type | KRASmutant | ||||
---|---|---|---|---|---|---|
L-L | O/MM | L-L | O/MM | L-L | O/MM | |
Evaluable patients | 25 | 32 | 12 | 18 | 13 | 14 |
Objective response (%; 95% CI) | 21 (84; 69 to 99) | 24 (80; 64 to 96) | 12 (100) | 15 (80; 59 to 100) | 9 (67; 40 to 94) | 9 (80; 54 to 100) |
Partial response | 18 | 22 | 10 | 13 | 8 | 9 |
Complete response | 3 (12) | 2 (6) | 2 (17) | 2 (11) | 1 (8) | - |
Stable disease | 2 | 3 | - | 2 | 2 | 3 |
Progressive disease | 2 | 3 | - | 1 | 2 | 2 |
Liver metastasectomies, N (%) | 17 (68) | 1 (3) | 10 (83) | 1 (6) | 7 (54) | - |
Pathologic complete responses | 2 (12) | - | - | - | 2 | - |
Overall activitya, N (%) | 20 (80) | 3 (9) | 12 (100) | 3 (17) | 8 (62) | - |
Median PFS, months | 17 | 12 | 21 | 12 | 11 | 11 |
Range | 3-69+ | 1+44 | 8-69+ | 4-44 | 3-60+ | 1+37 |
Progression events | 20 | 27 | 10 | 15 | 10 | 12 |
P value | 0.034 | 0.044 | 0.354 | |||
Median OS, months | 47 | 21 | 47 | 28 | 39 | 19 |
Range | 8-69+ | 1+66+ | 18+69+ | 1+66+ | 8-60+ | 1+59+ |
Deaths | 12 | 23 | 4 | 13 | 8 | 10 |
P value | 0.013 | 0.017 | 0.225 |